Immuno-Oncology Market Could Generate Peak Sales over $35 Billion by 2022

NEW YORK–(BUSINESS WIRE)– BioPharm
Insight (BPI), the most comprehensive life science market
intelligence and analytics solution, today announced the release of its Immuno-Oncology
Report, addressing toxicity and cost concerns for checkpoint
inhibitors and CAR-Ts as well as the combination potential of vaccines.

Get the Report: http://www.biopharminsight.com/immuno-oncology-report-december-2016

The two main approved checkpoint inhibitors, Merck’s (NYSE:MRK) Keytruda
and Bristol-Myers Squibb’s (NYSE:BMY) Opdivo, continue to take center
stage with trials showing varying levels of efficacy as they attempt to
expand approvals into additional cancer indications. Opdivo is forecast
to have global sales of more than $12 billion by 2022, surpassing
projected sales of fellow PD-1 inhibitor Keytruda, which is predicted to
have global sales of $7.7 billion during the same year.

In the CAR-T space, durable remissions seen in certain hematological
cancers, especially in relapsed or refractory B-cell acute lymphoblastic
leukemia (B-ALL), may translate to expansions into other liquid cancers
lacking response to standard therapies. Yet the use of CAR-T cells is
also currently limited by potentially severe toxicities, as exemplified
by recent news headlines on Juno Therapeutics’ (NASDAQ:JUNO) Phase II
JCAR015 ROCKET trial, which was put on clinical hold following the death
of two adult ALL patients.

Various therapeutic vaccines generating specific immune responses are
under investigation in several tumor types, with some of them being
closely looked at for their combination potential with checkpoint
inhibitors. Argos Therapeutics’ (NASDAQ:ARGS) is developing AGS-003, an
autologous dendritic cell–based immunotherapy in renal cell carcinoma
(RCC). In cervical cancer, experts say Advaxis’ (NASDAQ:ADXS) Phase III
study with axalimogene filolisbac (AXAL) could best exploit the
vaccine’s potential by studying it in the adjuvant setting.

“What we are seeing today in the Immuno-oncology space could well be the
tip of the iceberg in terms of innovative therapies, but the field also
has to contend with clear challenges in development and on the market,”
said Querida Anderson, editor in chief at BioPharm Insight.
“Going beyond anti-CTLA4/PD1/PDL1 mAbs and developing sound combination
possibilities are among key ongoing endeavors.”

In partnership with The
Conference Forum, Anderson will be moderating BPI’s panel
discussion, “Immuno-Oncology:
Filtering the Hype for the Next Wave of Targets,” taking place in
San Francisco on January 9^th. The discussion will build on
topics discussed in the featured Immuno-Oncology
Report, including next-generation Immuno-oncology therapeutics,
clinical trial design considerations, market traction and changing
reimbursement dynamics.

Panelists include:

• Axel Hoos, M.D., Ph.D., Senior Vice President for Oncology Research
  and Development at GlaxoSmithKline
• Ira Mellman, Ph.D, Vice President of Cancer Immunology at Genentech
• Lindee Goh, Partner at Tapestry Networks
• Omir Hamid, M.D., Chief of Translational Research and Immunotherapy
  and Director for Melanoma Therapeutics at The Angeles Clinic
• Ramy Ibrahim, M.D., Vice President and Head of Research and
  Development for the Parker Institute for Cancer Immunotherapy

Learn more about the Immuno-oncology panel: http://www.biopharminsight.com/events/biopharm-insight-exclusive-event

Learn more about the Immuno-oncology field with BioPharm Insight’s full
report: http://www.biopharminsight.com/immuno-oncology-report-december-2016

Tweet
This: .@BioPharmInsight
releases #ImmunoOncology report on recent developments & upcoming
catalysts: bit.ly/2ghFMkx

About BioPharm Insight

BioPharm Insight is the most comprehensive life science market
intelligence and analytics solution, featuring a team of investigative
journalists writing exclusive news and thousands of healthcare data
points, aggregated into one centralized source. In addition to the
proprietary articles, BioPharm Insight is currently tracking
250,000 management and R&D contacts, 7,500 biopharma companies with full
pipeline data, 120,000 investigational and approved drug profiles,
28,000 M&A and licensing deals, 10,000 extended sales forecasts and
epidemiology profiles for hundreds of indications. Meet with BioPharm
Insight in person during the 35^th
Annual J.P. Morgan Conference in January 2017. Learn more at www.biopharminsight.com
and follow us: @BioPharmInsight.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161207005313/en/